U.S. patent application number 17/575276 was filed with the patent office on 2022-08-11 for method of preventing covid-19 infection.
The applicant listed for this patent is Sabine Hazan. Invention is credited to Sabine Hazan.
Application Number | 20220249547 17/575276 |
Document ID | / |
Family ID | |
Filed Date | 2022-08-11 |
United States Patent
Application |
20220249547 |
Kind Code |
A1 |
Hazan; Sabine |
August 11, 2022 |
METHOD OF PREVENTING COVID-19 INFECTION
Abstract
A product for preventing COVID-19 infection in an individual,
the product comprising a combination of vitamin C, vitamin D, and
zinc. The combination comprises 1,000 mg to 10,000 mg of vitamin C,
3,000 IU to 40,000 IU of vitamin D, and 25 mg to 75 mg of zinc. The
combination is administered daily for two or more days for
prophylaxis, or the combination is administered weekly over a
period of two or more weeks for prophylaxis.
Inventors: |
Hazan; Sabine; (Ventura,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Hazan; Sabine |
Ventura |
CA |
US |
|
|
Appl. No.: |
17/575276 |
Filed: |
January 13, 2022 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
17114271 |
Dec 7, 2020 |
11278520 |
|
|
17575276 |
|
|
|
|
63002494 |
Mar 31, 2020 |
|
|
|
63022368 |
May 8, 2020 |
|
|
|
International
Class: |
A61K 33/30 20060101
A61K033/30; A61K 31/375 20060101 A61K031/375; A61K 31/59 20060101
A61K031/59; A61P 31/14 20060101 A61P031/14 |
Claims
1. A product for preventing COVID-19 infection in an individual,
the product comprising a combination of: a) vitamin C; b) vitamin
D; and c) zinc.
2. The product of claim 1, wherein the combination is administered
weekly over a period of two or more weeks for prophylaxis.
3. The product of claim 1, wherein the combination is administered
daily over a period of two or more days for prophylaxis.
4. The product of claim 1, wherein the combination comprises: a)
1,000 mg to 10,000 mg of vitamin C; b) 3,000 IU to 40,000 IU of
vitamin D; and c) 25 mg to 75 mg of zinc; wherein the combination
is administered daily for two or more days for prophylaxis.
5. The product of claim 4, wherein the combination is administered
weekly over a period of two or more weeks for prophylaxis.
6. The product of claim 4, wherein the combination is administered
daily over a period of two or more days for prophylaxis.
7. The product of claim 1, wherein the combination comprises: a)
3,000 mg of vitamin C; b) 3,000 mg of vitamin D; and c) 50 mg of
zinc.
8. The product of claim 4, wherein the combination comprises: b)
3,000 mg of vitamin C; c) 3,000 mg of vitamin D; and d) 50 mg of
zinc.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. Non-Provisional
patent application Ser. No. 17/114,271, titled "Method of
Preventing COVID-19 Infection," filed Dec. 7, 2020, which claims
priority to U.S. Provisional Application Ser. No. 63/002,494,
titled "Method of Using Vitamin C, Vitamin D, Zinc, and Optionally
Hydroxychloroquine, to Prevent COVID-19 Infection," filed Mar. 31,
2020, and also claims priority to U.S. Provisional Application Ser.
No. 63/022,368, titled "Method of Using Vitamin C, Vitamin D, Zinc,
and Optionally Hydroxychloroquine, to Prevent COVID-19 Infection,"
filed May 8, 2020, the contents of which are incorporated by
reference in their entirety.
BACKGROUND
[0002] COVID-19 is a novel betacoronavirus that originated in bats
in the city of Wuhan, China. This disease has rapidly spread to
become a worldwide pandemic. Scientists have identified the
molecular structure of the spike glycoproteins on the surface of
the virus, which are what allow the virus to "stick" to its target,
and in this case the human lung. The virus has a very similar
sequence and structure to the coronavirus that causes SARS, with
the exception of the receptor binding domain. In this domain there
is a loopy, flexible glycyl in place of a rigid prolyl, which
allows it to tightly bind to a hydrophobic pocket in the receptor,
ACE2.
[0003] Thus, there is a significant unmet need for preventing this
viral infection.
SUMMARY
[0004] The present invention addresses this need. The invention is
directed to a method of preventing COVID-19 infection in a healthy
individual, the method comprising the steps of:
[0005] a) providing the healthy individual;
[0006] b) administering, on day 1, 1,000 mg to 10,000 mg of vitamin
C, 1,000 mg to 40,000 mg of vitamin D, and 25 mg to 75 mg of
zinc;
[0007] c) administering daily, on days 2 through 7, 1,000 mg to
10,000 mg of vitamin c and 25 mg to 75 mg of zinc; and
[0008] d) repeating steps b) and c) for 1 to 23 weeks.
[0009] Optionally, step c) comprises administering daily, on days 2
and 3, 10,000 mg of vitamin c and 50 mg of zinc; and administering
daily, on days 4 through 7, 3,000 mg of vitamin c and 50 mg of
zinc.
[0010] Optionally, step c) comprises assessing the patient for
potential adverse events, serious adverse events, and COVID-19
symptoms.
[0011] Optionally, steps b) and c) comprise administering selenium,
copper and other vitamins that are appropriate supplements for
vitamin C, vitamin D or zinc.
DRAWINGS
[0012] These and other features, aspects and advantages of the
present invention will be better understood with reference to the
following description, appended claims, and accompanying drawings
where:
[0013] FIG. 1 is a flow chart depicting the steps of a first method
of preventing infection with COVID-19.
DETAILED DESCRIPTION OF THE INVENTION
[0014] The following discussion describes in detail one embodiment
of the invention with several variations of that embodiment. This
discussion should not be construed, however, as limiting the
invention to those particular embodiments. Practitioners skilled in
the art will recognize numerous other embodiments as well.
[0015] This invention describes a method of triple therapy for
preventing a COVID-19 infection.
[0016] Definitions
[0017] As used herein, the following terms and variations thereof
have the meanings given below, unless a different meaning is
clearly intended by the context in which such term is used.
[0018] The terms "a," "an," and "the" and similar referents used
herein are to be construed to cover both the singular and the
plural unless their usage in context indicates otherwise.
[0019] As used in this disclosure, the term "comprise" and
variations of the term, such as "comprising" and "comprises," are
not intended to exclude other additives, components, integers,
ingredients or steps.
[0020] The present invention is directed to a method of preventing
COVID-19 infection in an individual. The method comprises
administering three different supplements. The supplements
comprise:
[0021] Vitamin C, Vitamin D, Zinc, and any mixtures thereof.
[0022] The length of preventative treatment of the present
invention can be as long as necessary. However, regardless of the
length of treatment, Vitamin C is provided at 10,000 mg daily for
the first three days of treatment, and then 3000 mg daily
thereafter. This 10,000 mg of Vitamin C can be broken up into two
doses, one taken in the morning and one taken at night.
[0023] Vitamin D is provided at 40,000 mg one day every 4 weeks (or
however many weeks the preventative treatment lasts). This 40,000
mg of Vitamin D can be broken up into two doses, one taken in the
morning and one taken at night.
[0024] Zinc is provided at 50 mg per day ongoing, for the length of
the preventative treatment. This 50 mg of Zinc can be broken up
into two doses, one taken in the morning and one taken at
night.
[0025] On Day 1 (Week 1), the patient provides verbal informed
consent, the patient reviews prior (previous 3 months) and
concomitant medications and the patient receives the three
different supplements: Vitamin C, Vitamin D, and Zinc. The patient
takes 10,000 mg of Vitamin C, 40,000 mg of Vitamin D, and 50 mg of
zinc.
[0026] On Days 2 and 3 (Week 1), the patient takes 10,000 mg of
Vitamin C and 50 mg of zinc daily. This 3,000 mg can be broken up
into two 1500 mg doses, one taken in the morning and one taken at
night. The patient is called on the phone for assessment for
potential adverse events (AE) and serious adverse events (SAE), and
any COVID-19 symptoms.
[0027] On Days 4-7 (Week 1), the patient takes 3,000 mg of Vitamin
C and 50 mg of zinc daily.
[0028] On Day 8 (Week 2), the patient takes 3,000 mg of Vitamin C,
40,000 mg of Vitamin D, and 50 mg of zinc.
[0029] On Days 9-14 (Week 2), the patient takes 3,000 mg of Vitamin
C and 50 mg of zinc daily.
[0030] Weeks 3-24 continue with the same protocol identified above
for Week 2.
[0031] During Weeks 1-23, the patient is called weekly on the phone
for assessment for adverse events and serious adverse events, and
any COVID-19 symptoms. The list of prior and concomitant
medications is also updated.
[0032] During Week 24, the patient is called to the clinic for
evaluation to include assessment for potential adverse events and
serious adverse events, to update the list of prior and concomitant
medications, to perform confirmatory COVID-19 testing, and to
perform blood testing.
[0033] Optionally, Vitamin C dosage can range from 1000mg to
10,000mg per day, Vitamin D dosage can range from 1000 IU to 40000
IU per day, Zinc (the zinc can be any type or form of zinc) dosage
can range from 25-75 mg per day. As noted above, all daily doses of
Vitamin C, Vitamin D and Zinc can be broken up into two daily
doses, wherein one dose is taken in the morning and one dose is
taken in the evening. For all protocols provided in this
application, when a dosage range is provided, any dosage amount
that is included in that range can be administered. Accordingly,
the invention is not limited to the dosage ranges disclosed, and
includes all dosage amounts contained in those ranges.
[0034] The protocol provided in this application can also include
selenium, copper and other vitamins that are deemed appropriate
supplements for Vitamin C, Vitamin D or Zinc or, to counteract the
negative depletion of certain vitamins, like copper or
selenium.
[0035] Treatment can be for one day or consecutive or repeated in 2
weeks, 1 month, 6 months or 1 year.
[0036] The Vitamin C, Vitamin D and Zinc, and mixtures thereof, can
be administered orally, in the form pills/lozenges, an aerosolized
spray, or a food substance such as a liquid drink or yogurt
composition. Optionally, the Vitamin C, Vitamin D and Zinc can be
administered in the form of a nasal spray or a topical application,
such a lotion or spray for administration on the individual's
skin.
[0037] Table 1 outlines the schedule of events for this
protocol.
TABLE-US-00001 TABLE 1 Assessment Screening (Day 1) Day 2 Day 3 Day
4 Weeks 1-23 Weeks 24/ET(.+-.4 d) Informed Consent &
Demographics X Review of Prior and Concomitant Medications X
Physical Exam X Vitals.sup.a X Prescription of vitamin C, vitamin
D, and zinc X Update list of prior concomitant medications X X X
Ask about AE and SAE X X X X Update dose of Vitamin C to 3000 mg
daily X Evaluation for COVID-19 symptoms X X COVID-19 testing X a.
Blood draw for future testing.sup.b X .sup.aVitals to include
height (only at first visit), weight, blood pressure (following 5
minutes sitting), pulse, respiratory rate, temperature, and oxygen
saturation. .sup.bFuture testing will require separate informed
consent and can include antibody or cytokine testing.
[0038] COVID-19 sample collection period (to be conducted by
patient's physician if infection is suspected at any time during
the study or after). Nasopharyngeal (NP) and oropharyngeal (OP)
swabs will be collected according to CDC protocol--which include
synthetic fiber swabs with plastic shafts. The NP swabs are
collected by insertion of a swab into the nostril parallel to the
palate. The swab is left in place a few seconds to allow it to
absorb secretions. The OP swabs are inserted into the oropharynx
parallel to the palate, avoiding the tongue. The swab is left in
place a few seconds to allow it to absorb secretions. These swabs
are immediately placed in sterile tubes with 2-3 mL of viral
transport media. The tubes are placed in biohazard bags then boxes
and couriered to the local Public Health Lab.
[0039] The above protocols can be used to prevent infection with
other viruses (not just COVID-19), including other flu viruses.
[0040] The above protocols can also be used to treat Autism,
Parkinson's, Alzheimer's and other neurological diseases.
EXAMPLES
Example 1: Successful Treatment of COVID-19 Infected Outpatients
and Prophylaxis of Immediate Associates
[0041] Objective: to successfully treat COVID-19 infected
outpatients and prophylaxis of immediate associates.
[0042] Procedure: Prospective COVID-19 infected individuals were
diagnosed using a Pangea DNA/RNA Shield.TM. Collection Tube to
obtain a nasopharyngeal swab and PCR+ve patients were entered into
the study. They were immediately commenced on a 10 day course of
Hydroxychloroquine (200 mg, twice a day, for 10 days), Azithromycin
extended release (500 mg on day 1, then 250 mg a day for days
9-10), zinc (50 mg a day for days 1-10), Vitamin D (3000 IU a day
for days 1-10) and Vitamin C (3000 mg a day for days 1-10). Some
individuals lived alone, otherwise immediate partners and family
deemed to be most exposed were given a prophylactic which comprised
hydroxychloroquine 200 mg twice a day on day 1 only with Zinc,
Vitamin C and Vitamin D for given at the same doses as above for
days 1-10.
[0043] Results: In 11 families a total of 21 family members were
identified to be PCR COVID-19 positive index cases and were treated
with the above treatment protocol while 22 exposed associates with
negative PCR were given the above prophylaxis protocol. This is
shown below in Table 24. All 21 index cases were cured of COVID-19
infection as judged by the repeat swab PCR on day 10 and
accompanying symptom resolution. None of the 22 highly exposed
associates developed COVID-19 infection when retested on day 10
(day 14 in Family 10) in spite of close co-habitation with the
infected index cases. TABLE 2: Results from families received
10-day course of daily HCQ (200 mg bd), AZ extended release (500 mg
day 1, then 250 mg), zinc (50 mg), Vitamin D (3000 IU) and Vitamin
C (3000 mg)
TABLE-US-00002 TABLE 2 After treating Age with HAZDPAC After
treating (years)- Cured/PCR test ZINCD+H Patient/s sex of the
Comorbidities positive/negative/ family member Family treated
patient of the patients other symptoms prophylaxed #1 1 23-male
Asthma Negative Parents PCR-day 10 overweight, diabetes, father
with heart disease never got the disease #2 3 60-male Asthma All 3
patients Mother didn't (father) cured get the virus 18-male (son)
16-female (daughter) #3 1 40-female Avoided Sever multiple Husband
did not intubation by symptoms turn positive leaving hospital
resolved at home #4 2 78-male BCG+COPD, Both cured Daughter,
77-female diabetes, heart son-in-law and 2 disease (heart grandkids
didn't surgery month catch the virus prior Pacemaker, BCG #5 3
56-male Unable to Started treatment Wife never 27-male eat or drink
on day 10, Sever got the disease 24-female Asthma symptoms resolved
Cured #6 1 56-female Admitted to Husband never hospital- got the
disease sent home, as two kids were sick with fever. All recovered
with vitamins #7 1 44-female Cured, Husband and autoimmune 4 kids
never issues started got the disease #8 3 52-female Lupus Cured
Boyfriend (54 y) 53-male Severe asthma Cured with Diabetes, 19-male
Cured son (18) and daughter (16) never got the disease #9 2
45-female Both cured from Husband and 16-male severe symptoms
daughter never of cough and fever got the disease #10 2 44-male
Cured from loss of Mother (50 y) 25-female smell, fever, cough
never got 21-female Cured the disease Partially treated with
HAZDPAC- slowly turned -ve #11 1 33-female No ICU nurse Boyfriend
never recovered got the disease
[0044] Apart from the families a further 11 single infected
individuals found to be swab PCR positive were treated with the
above treatment protocol. This is shown below in Table 3. All were
also successfully cured of the infection.
TABLE-US-00003 TABLE 3 Age (years)- Comorbidities/ After treating
sex of symptoms with HAZDPAC Patient the patient of the patients
Cured/not #1 44-female Asthma Cured (no BCG in childhood) #2
81-male Diarrhea Cured #3 52-female Fever Cured #4 66-male Valve
surgery Cured #5 29-female Asthma Cured (no BCG in childhood) #6
50-female Auto immune thyroiditis, Cured sever cough and fever #7
43-male Cough, desaturation of oxygen Cured #8 53-male Diarrhea,
cough, fever, Cured desaturation of oxygen #9 44-female Autoimmune
history, fever, Cured increase heart rate #10 44-female
Pneumothorax discharged Cured from ICU with COVID-19 #11 43-male
Fever +ve Covid-19 PCR Cured
[0045] A further 9 individuals recently closely exposed to Covid-19
infected persons were given the prophylaxis protocol outlined
above. The prophylactic worked very well with no exposed person
acquiring the infection. This is shown in Table 4.
TABLE-US-00004 TABLE 4 Age (years) & After treating Individual
details of the individual with ZINCD+H #1 Mother of 16 year old
Prophylaxed and child who had COVID-19 never got the disease #2
24-female, ICU nurse- Prophylaxed and multiple exposures never got
the disease #3 47-male, cardiologist exposed Prophylaxed and to +ve
patients never got the disease #4 70-male medical director
Prophylaxed and of a hospital (exposed to never got the disease
numerous doctors with COVID-19) #5 55-male anaesthesiologist
Prophylaxed and (intubates COVID-19 patients) never got the disease
#6 55-ICU nurse (worked on Prophylaxed and COVID-19 floor) never
got the disease #7 40-ICU nurse many Prophylaxed and Covid-19
patients never got the disease #8 53-Doctor with pancreatitis
Prophylaxed and never got the disease #9 28-Paramedic-healthy
Prophylaxed and never got the disease
[0046] Discussion: It was demonstrated that a 10 day combination of
hydroxychloroquine, azithromycin (for 5 days only), zinc with
vitamin D and vitamin C, can result in uniform cure of COVID-19
infection when used in an outpatient population. The prophylaxis
treatment noted above for those closely exposed to proven, infected
patients can completely prevent spread of COVID-19. This
combination of test-and-treat permits abolishing of new outbreaks
of infection such as a `next wave`--by avoiding quarantine to treat
the infected and give prophylactics to surrounding staff and
family.
[0047] In conclusion, this is an effective anti-Covid-19 therapy as
well as an effective prophylactic combination capable of arresting
the spread of coronavirus infection throughout the community. This
is achieved by treating the index case and the surrounding
associates of the patient as early as possible after infection is
identified and then treating the people they live with and close
associates.
[0048] Having thus described the invention, it should be apparent
that numerous structural modifications and adaptations may be
resorted to without departing from the scope and fair meaning of
the instant invention as set forth herein above and described
herein below by the claims.
* * * * *